MODIFICATION OF ALPHA-CRYSTALLIN CHAPERONE FUNCTION
α-晶状体蛋白伴侣功能的修饰
基本信息
- 批准号:2430394
- 负责人:
- 金额:$ 13.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-06-01 至 2000-05-31
- 项目状态:已结题
- 来源:
- 关键词:SDS polyacrylamide gel electrophoresis affinity chromatography aging animal tissue binding proteins cataract crystallins diabetes mellitus disulfide bond electrospray ionization mass spectrometry fast atom bombardment mass spectrometry glutathione glycation high performance liquid chromatography human tissue laboratory rat mass spectrometry molecular chaperones oxidation posttranslational modifications protein denaturation protein structure function western blottings
项目摘要
The objective of this proposal is to elucidate the effect of some common
posttranslational modifications of alpha-crystallin (alphaA and alphaB) on
the molecular chaperone property, i.e., the ability of alpha-crystallin to
protect other proteins from denaturation and aggregation. By choosing
biologically relevant modifications different domains of alphaA- and
alphaB-crystallins will be targeted for in vitro structural modifications
which in turn will be correlated with changes in chaperone function.
Studying in vitro modification will facilitate the characterization of in
vivo modifications that cause a decline in chaperone like property of
human alpha-crystallin. This is the first study ever where
posttranslational modifications that occur in vivo and that can be
inflicted in vitro will be correlated with chaperone activity and
chaperone-target protein binding.
The specific aims of this proposal are based on our most recent findings
that glycation, oxidation and mixed disulfide formation have inhibitory
effects on alpha-crystallin chaperone function and that both aging and
diabetes decrease the chaperone property. The following specific aims are
hypothesis driven, each designed to test a specific hypothesis: 1) In
vitro modifications of calf or young human alpha-crystallin by oxidation
with H2O2, by glycation with ascorbic acid and fructose, and by mixed
disulfide formation with GSSG will be used to test the hypothesis that
such posttranslational modifications will influence the chaperone function
as determined by the ability of alpha-crystallin to protect beta- and
gamma-crystallin from thermal denaturation and aggregation. In addition,
we will study the combined effect of more than one type of modification
hoping to show a synergistic effect by two treatments. 2) With both alphaL
and alphaH fractions from 1 month to 90 years old human lenses it will be
shown whether with increasing age increasing levels of posttranslationally
modified alpha-crystallin with altered chaperone function accumulates. 3)
Since diabetic lenses are exposed to higher levels of oxidation and
glycation than age-matched non-diabetic lenses we will test the
possibility that the alpha-crystallin chaperone function is altered even
more in diabetic human or rat lenses. 4) We will identify the protein
modifications in alphaA- and alphaB-crystallins that will be introduced in
vitro or that occur in vivo by mass spectral analysis and correlate with
changes in chaperone function including chaperone-target protein binding.
These analyses will identify the types of modifications that produce a
decrease in the chaperone property. 5) We will investigate the mechanism
of the loss of chaperone function due to in vitro modifications or in vivo
modifications during aging or diabetes. We will test the hypothesis that
posttranslational modifications affect the chaperone-target protein
binding leading to reduced chaperone function.
本提案的目的是阐明一些常见的
α-晶状体蛋白(α A和α B)的翻译后修饰
分子伴侣特性,即,α-晶状体蛋白
保护其他蛋白质免于变性和聚集。 通过选择
生物学相关修饰α A-和
α B-晶体蛋白将被靶向用于体外结构修饰
这又将与伴侣蛋白功能的变化相关。
体外修饰的研究将有助于表征在体外的修饰。
体内修饰导致蛋白伴侣样性质的下降,
人α-晶状体蛋白。 这是有史以来第一个
在体内发生的翻译后修饰,
在体外造成的伤害将与伴侣活性相关,
伴侣蛋白-靶蛋白结合。
这项建议的具体目标是基于我们最近的调查结果
糖化、氧化和混合二硫键形成具有抑制作用,
对α-晶状体蛋白伴侣功能的影响,
糖尿病降低了伴侣蛋白的特性。 以下具体目标是
假设驱动,每个设计用于测试特定的假设:1)在
通过氧化对小牛或年轻人α-晶状体蛋白的体外修饰
用H2 O2,用抗坏血酸和果糖糖化,
将使用GSSG形成二硫化物来检验以下假设:
这种翻译后修饰将影响分子伴侣的功能
如通过α-晶状体蛋白保护β-和
γ-晶状体蛋白的热变性和聚集。 此外,本发明还提供了一种方法,
我们将研究一种以上改性的综合效果
希望通过两种处理来显示协同效应。2)与alphaL
从1个月到90岁的人类晶状体中的α H分数,
显示随着年龄的增长,
具有改变的伴侣蛋白功能的修饰的α-晶状体蛋白积累。第三章
由于糖尿病镜片暴露于更高水平的氧化,
糖化比年龄匹配的非糖尿病镜片,我们将测试
α-晶状体蛋白伴侣蛋白功能改变的可能性,
糖尿病患者或大鼠的晶状体中更多。4)我们将鉴定出
将引入的α A-和α B-晶体蛋白中的修饰
体外或体内发生,并与
分子伴侣功能的变化,包括分子伴侣-靶蛋白结合。
这些分析将确定产生
减少伴侣的属性。5)我们将研究其机制
由于体外修饰或体内修饰导致的伴侣蛋白功能丧失
在衰老或糖尿病期间的变化。 我们将检验这个假设,
翻译后修饰影响伴侣蛋白靶蛋白
结合导致伴侣蛋白功能降低。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Edathara C Abraham其他文献
Edathara C Abraham的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Edathara C Abraham', 18)}}的其他基金
MODIFICATION OF ALPHA-CRYSTALLIN CHAPERONE FUNCTION
α-晶状体蛋白伴侣功能的修饰
- 批准号:
6126661 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
Modification of Alpha-Crystallin Chaperone Function
α-晶状体蛋白伴侣功能的修饰
- 批准号:
6770724 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
Modification of Alpha-Crystallin Chaperone Function
α-晶状体蛋白伴侣功能的修饰
- 批准号:
8197593 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
MODIFICATION OF ALPHA-CRYSTALLIN CHAPERONE FUNCTION
α-晶状体蛋白伴侣功能的修饰
- 批准号:
6384662 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
Modification of Alpha-Crystallin Chaperone Function
α-晶状体蛋白伴侣功能的修饰
- 批准号:
6931038 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
MODIFICATION OF ALPHA-CRYSTALLIN CHAPERONE FUNCTION
α-晶状体蛋白伴侣功能的修饰
- 批准号:
2165678 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
Modification of Alpha-Crystallin Chaperone Function
α-晶状体蛋白伴侣功能的修饰
- 批准号:
8374126 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
MODIFICATION OF ALPHA-CRYSTALLIN CHAPERONE FUNCTION
α-晶状体蛋白伴侣功能的修饰
- 批准号:
6635645 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
MODIFICATION OF ALPHA-CRYSTALLIN CHAPERONE FUNCTION
α-晶状体蛋白伴侣功能的修饰
- 批准号:
6518548 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
MODIFICATION OF ALPHA-CRYSTALLIN CHAPERONE FUNCTION
α-晶状体蛋白伴侣功能的修饰
- 批准号:
2888498 - 财政年份:1996
- 资助金额:
$ 13.87万 - 项目类别:
相似海外基金
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10506915 - 财政年份:2021
- 资助金额:
$ 13.87万 - 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
- 批准号:
10325006 - 财政年份:2021
- 资助金额:
$ 13.87万 - 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
- 批准号:
1746198 - 财政年份:2018
- 资助金额:
$ 13.87万 - 项目类别:
Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
- 批准号:
512537-2017 - 财政年份:2017
- 资助金额:
$ 13.87万 - 项目类别:
University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
- 批准号:
1404605 - 财政年份:2014
- 资助金额:
$ 13.87万 - 项目类别:
Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
- 批准号:
1263713 - 财政年份:2013
- 资助金额:
$ 13.87万 - 项目类别:
Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
- 批准号:
425749-2012 - 财政年份:2012
- 资助金额:
$ 13.87万 - 项目类别:
Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
- 批准号:
1159886 - 财政年份:2012
- 资助金额:
$ 13.87万 - 项目类别:
Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
- 批准号:
19560760 - 财政年份:2007
- 资助金额:
$ 13.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
- 批准号:
234753-2000 - 财政年份:2003
- 资助金额:
$ 13.87万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




